Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 17/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975453 | 0.82 | PRKCZ (0.61) | PRKCIPRKCZ | |
| SCHEMBL14977500 | 0.81 | PRKCI (0.61) | PRKCIPRKCZ | |
| SCHEMBL14976783 | 0.81 | PRKCI (0.61) | PRKCIPRKCZ | |
| SCHEMBL14975626 | 0.79 | PRKCI (0.63) | PRKCIPRKCZ | |
| SCHEMBL16195347 | 0.79 | PRKCI (0.64) | PRKCI | |
| SCHEMBL16194074 | 0.79 | PRKCI (0.59) | PRKCI | |
| SCHEMBL14986348 | 0.78 | PRKCI (0.67) | PRKCIPRKCZ | |
| SCHEMBL14986564 | 0.78 | PRKCI (1.00) | PRKCI | |
| SCHEMBL14974719 | 0.77 | PRKCI (0.64) | PRKCIPRKCZ | |
| SCHEMBL14975008 | 0.77 | PRKCI (0.64) | PRKCIPRKCZLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604994-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-3048106-A1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048106-A1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2782917-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885LIMK1 1270/4885 |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PRKCZ 15/4885LIMK1 1387/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PRKCZ 15/4885LIMK1 1387/4885 |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885LIMK1 1270/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885LIMK1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.